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     Perforin(p) is the primary mediator of short term cytotoxicity, it is accumulated in response to 
proinflammatory  cytokines and stored in T lymphocyte , NK cells and NKT cells are released upon 
activation. Perforin is a prototypical cytotoxic molecule involved in cell mediated immunity against 
various pathogens , alloantigens and particularly different tumors.The purpose of this study was to 
determine perforin level in prostate cancer (P.Ca) and Benign Prostatic Hyperplasia (BPH).                                                                                                                                        
This study was performed on 59 patients consisting of 28 patients with P.Ca and 31 patients with BPH. 
Perforin and PSA levels were measured in cancer and BPH patients  using ELISA method.   
Mean Perforin value was significantly lower in P.Ca patients than in BPH patients ( p < 0.01)  where as 
mean serum PSA level was significantly higher in the cancer patients in comparison to the BPH group (P 
< 0.01). Our finding indicate probability of problem in expression of cytotoxic molecule ,perforin  in and 
around the tumor. 
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INTRODUCTION 
     Prostate cancer,a common malignant disease 
in males[1], is the second leading cause of death 
from cancer in men in both Europe and the 
United States[1].The Iranian Annual of National 
Cancer Registration Report  in 2006, the 
number of Prostate cancer registered is about 
3733 cases with ASR 12.80 per 100,000 
population.[ 2].In Iran ,prostate cancer is the  3
th
  
most common cancer in male population 
following gastric and bladder cancers and is the 
5
th
 leading cause of death due to cancer in 
men[3].Naturally human body using of the 
many mechanism for inhibition of foundation of 
cancer. Cytotoxic T lymphocyte and Natural 
killer cells are one of the primary mechanisms 
used by higher organisms to eliminate viruses 
and transformed cells.Apoptosis is an innate 
mechanism of programmed cell death that  can 
be induced by two pathways: 
 a) granuledependent exocytosis pathway  
 b) Fas-FasL intercellular linkage-mediated 
pathway [4,5].This pathway is established 
through intracellular signaling after target cell 
recognition by a cytotoxic lymphocyte (NK or 
cytotoxicT cell). In exocytosis or degranulation, 
there is microtubules mobilization that leads the 
preformed granules or lysosomes of the 
cytotoxic cell towards the point of contact with 
the target cell, releasing stored lytic 
molecules[6,7]. 
The lytic granule contains a proteoglycan matrix 
that maintains protease enzymes in an inactive 
stage and avoiding from self-destruction 
[6,7].There is  a novel perforin inhibitor 
associated with cytotoxic T cell granules and 
termed it Cytotoxic Regulatory Protein 2 
(CxRP2). The protein disulfide isomerase A1 
had CxRP2 activity and indicated that protein 
disulfide isomerases, in the ER or elsewhere, 
may protect T cells from their own perforin [8]. 
 The lytic molecules stored in granules that 
induce apoptosis are perforin, granzymes (Grzs) 
and granulysin[9]. 
In this pathway, cytoplasmic granule toxins — 
predominantly  perforin— and a family of 
structurally related serine proteases (granzymes) 
with various substrate specificities are secreted 




by exocytosis and together induce apoptosis of 
the target cell[9]. The granule-exocytosis 
pathway powerfully activates cell-death 
pathways that operate through the activation of 
apoptotic cysteine proteases (caspases).The 
second pathway involves the engagement and 
aggregation of target-cell death receptors, such 
as FAS (CD95), by their cognate ligands, such 
as FAS ligand (FASL),on the killer-cell 
membrane,which results in classical caspase-
dependent apoptosis. The main function of the 
FAS–FASL pathway is to eliminate self-
reactive lymphoid cells[9]. 
Perforin is found in a soluble monomer shape 
within granules and, after the cytotoxic-
cell/target-cell junction, perforin is released by 
exocytosis. Once it is anchored, perforin begins 
the polymerization in the presence of Ca2+ to 
form cylindrical pores with an internal diameter 
of 5 to 20 nm[6,7]. The perforin pores can serve 
as passive conductos of granzymes and 
granulysin through the target cell membrane and 
could also allow an ionic exchange, which 
causes an osmotic unbalance and in 
consequence, the cell death[6]. 
It's a protein produced by cells of the prostate 
gland and  the blood level of PSA is often 
elevated in men with prostate cancer. In 
addition to prostatitis (inflammation of the 
prostate) and benign prostatic hyperplasia 
(BPH) (enlargement of the prostate) cause an 
elevation in PSA level . PSA levels of 4.0 
ng/mL and lower as normal[10,11,12]. 
The purpose of this study was to investigate 
serum level of perforin in patients with (P.Ca) 
and BPH. 
 
 MATERIALS AND METHODS 
     In this study 59 patients consisting of 28 
patients with P.Ca and 31 patients with BPH 
who preferred to Tajrish Shohada of Hospital 
were recruited. P.Ca and BPH patients were 
chosen based upon their serum PSA level and 
Digital rectal examinatrion(DRE). 
 The exclusion criteria for all subjects enrolled 
in this study were presence of immunological 
disorder , acute/chronic inflammatory disease 
and history on immune suppressive or radiation 
therapy. All participants gave their written 
informed consent and agreed to proceed with 
study protocol. 5 cc blood was collected from 
the subjects , serum was isolated and stored of   
-20c. The concentration of serum PSA of all 
study subjects was measured using the ELISA 
method (Diaplus Diagnostic, U.S.A). Serum 
perforin level was measured using the ELISA 
method(CUSABIO Company, china). 
TNM system was used for staging cancer in the 
prostate cancer group. 
 
 
Statistical  Analysis 
Result were expressed as mean±SD of 
experiments. Student's t-test  was used for 
comparison of the means between two groups, 
and one-way ANOVA for comparison between 
multiple groups. To assess correlation between 
GranzymeH and Estrogen,age,cancer stage 
correlation bivariate test was performed. For all 
tests, P<0.05 was considered statistically 
significant. Data were analyzed using SPSS 
software version 16. 
 
RESULT 
     In this study the mean age of the patients was 
68  ± 5.8 years (ages 56-85 years). As shown in 
Table 1 serum perforin level was significantly 
lower in P.Ca patients compared to the BPH 
patients( p < 0.01). 
 Where as serum PSA level was significantly 
higher in cancer patients in comparison to the 
BPH group ( p < 0.01). 
 
Table1:Perforin in the P.Ca and BPH  group 
 
Table 2: PSA in the P.Ca and BPH groups 
 
 




value         
<0.01 
 
max Min SD mean Group  
Perforin 
 
26.03 1.73 5.95 10.05 BPH 










14.2 1.9 2.22 4.015 BPH 
42 6.7 8.59 18.38 P.canc
er 
max min SD Mean N Stage 
16.22 1.92 4.27 6.87 17 1 
11.61 2.26 3.68 6.30 9 2 
13.17 1.99 7.90 7.58 2 3 




Pearson correlation analysis between PSA 
,Perforin and Age indicates a weak negative 
,non significant correlation between perforin 
and PSA in both P.Ca and BPH groups. In BPH 
group a positive correlation was observed 
between PSA and Age  (r = 0.34 , p value < 
0.05). We performed one way ANOVA test to 
compare perforin levels in different stages of 
cancer in  P.Ca patients , with reference to the 
results given in Table 3 , there was no 
significant difference in perforin levels in the 3 
different cancer stages ( p < 0.9). However PSA 
levels showed a significant difference in the 
three stages ( p < 0.05). 
DISCUSSION 
     The purpose of this study was to investigate 
serum level of perforin in patients with (P.Ca) 
and BPH. P.Ca and BPH are both related to 
chronic inflammatory process and are 
recognized as result of altered immune 
response[13]. Perforin is the primary mediator 
of short term cytotoxicity , it is accumulated in 
response to proinflammatory  cytokines and 
stored in T lymphocyte , NK cells and NKT 
cells are released upon activation. Studies on 
perforin deficient mice have confirmed the 
essential invivo role of perforin in target cell 
apoptosis induced by CTLs and NK cells , in 
immune responses to cancer and in certain 
infections[13]. 
In this study serum level of perforin was 
significantly lower in P.Ca patients in 
comparison to BPH patients. Ebelt et al  
reported that perforin expressing T lymphocytes 
are rare in BPH and particularly P.Ca tissue[14]. 
This finding is consistent with the observation 
of Takmadzic et al who also reported lower 
perforin expression in the BPH and P.Ca tissue 
although they did not find significant difference 
in total perforin expression in peripheral blood 
lymphocytes between P.Ca and BPH group[13-
14]. Negligible expression of perforin in T 
lymphocytes , NKT , NK cells may be result of 
tumor activity leading to the development of a 
chemical barrier around the tumor that probably 
inhibits infiltration and activation. 
In accordance to the result obtained by 
Takmadzic et al we did find a negative 
correlation between PSA and Perforin , 
[15],however this correlation was not statically 
significant ; which could be attributed to poor 
sample size . Poor sample size in this study 
could be also the reason we did not find a 
significant difference among perforin levels in 
the three cancer stage groups. 
In conclusion our finding indicates the 
possibility of problem existing in expression of 
perforin in and around the tumor. 
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